Telitacicept Clinical Trials

7 actively recruiting trials across 2 locations

Also known as: RC-18, RC18, RC18-L

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 4

Top Sponsors

Vor Biopharma2
RemeGen Co., Ltd.2
RenJi Hospital1
Nanjing University School of Medicine1
Liu Tian1

Indications

Lupus4
Systemic Lupus Erythematosus3
Cancer2
Primary Sjogren's Disease1
Lupus Nephritis (LN)1

Other5 trials

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

Phase 3

A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus

Phase 1

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

Phase 3

Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients

N/A

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Phase 2

Los Angeles, California1 trial

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

University of Southern California

Phase 3

Chicago, Illinois1 trial

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Chicago Clinical Research Institute Inc

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.